Clinical trial

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

NCT07208773

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-10-29

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2025-10-29Date precision: day

Registry last updated2026-06-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorsunresolved

Non Small Cell Lung Cancerunresolved

Small Cell Lung Cancerunresolved

Interventions

YL201DRUG

IvonescimabDRUG

Sponsors & collaborators

MediLink Therapeutics (Suzhou) Co., Ltd.lead sponsor

Akesobiocollaborator

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07208773 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.